Which patients with locally advanced prostate cancer will benefit from adjuvant or neoadjuvant hormone therapy with radiotherapy?
The addition of hormone therapy to radiotherapy should be offered primarily to patients with a Gleason score of 7-10. Determining the best timing and duration of adjuvant hormone therapy should be made in consultation with the patient, who should be well informed. It should be communicated to the patient that the optimal approach is unknown, and an approach that is most acceptable to the patient will be chosen. 3.4 Hormone therapy Hormone therapy is a treatment option for patients with cT3 prostate cancer who refuse external radiotherapy or for whom external radiotherapy is contraindicated. Given the risk of adverse events associated with hormone therapy, delayed initiation of therapy is preferred. What are the results of active monitoring without treatment in cT3 tumours? Active monitoring and initiation of hormone therapy when symptoms or metastases arise can be considered for patients with limited life expectancy (<10 years). Follow-up 4.1.2 Duration of follow-up After treatment for
Related Questions
- What are the expected outcomes of adjuvant or neoadjuvant hormone therapy in patients with localised prostate cancer?
- Should hormone therapy be continued in patients who develop hormone-resistant metastatic prostate cancer (HRPC)?
- When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
